SG11201803643TA - Virulence attenuated bacteria for treatment of malignant solid tumors - Google Patents
Virulence attenuated bacteria for treatment of malignant solid tumorsInfo
- Publication number
- SG11201803643TA SG11201803643TA SG11201803643TA SG11201803643TA SG11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA SG 11201803643T A SG11201803643T A SG 11201803643TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- basel
- rule
- malignant solid
- virulence attenuated
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001018 virulence Effects 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195490 | 2015-11-19 | ||
| PCT/EP2016/078084 WO2017085233A1 (en) | 2015-11-19 | 2016-11-17 | Virulence attenuated bacteria for treatment of malignant solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803643TA true SG11201803643TA (en) | 2018-06-28 |
Family
ID=54697464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803643TA SG11201803643TA (en) | 2015-11-19 | 2016-11-17 | Virulence attenuated bacteria for treatment of malignant solid tumors |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11166987B2 (https=) |
| EP (2) | EP3377094B1 (https=) |
| JP (1) | JP7060503B2 (https=) |
| KR (1) | KR102736981B1 (https=) |
| CN (1) | CN108472348B (https=) |
| AU (1) | AU2016358257B2 (https=) |
| BR (2) | BR112018009753B1 (https=) |
| CA (1) | CA3003563A1 (https=) |
| CY (1) | CY1124564T1 (https=) |
| DK (1) | DK3377094T3 (https=) |
| EA (1) | EA201890868A1 (https=) |
| ES (1) | ES2880431T3 (https=) |
| HR (1) | HRP20211191T1 (https=) |
| HU (1) | HUE055132T2 (https=) |
| IL (1) | IL259052B2 (https=) |
| LT (1) | LT3377094T (https=) |
| PL (1) | PL3377094T3 (https=) |
| PT (1) | PT3377094T (https=) |
| RS (1) | RS62152B1 (https=) |
| SG (1) | SG11201803643TA (https=) |
| SI (1) | SI3377094T1 (https=) |
| SM (1) | SMT202100423T1 (https=) |
| WO (1) | WO2017085233A1 (https=) |
| ZA (1) | ZA201803902B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102648293B1 (ko) | 2014-05-21 | 2024-03-15 | 우니페르시테트 바젤 | 세균 기반 단백질 전달 |
| IL259050B2 (en) | 2015-11-19 | 2024-03-01 | Univ Basel | Bacteria-based protein delivery |
| EP3957645A1 (en) | 2016-12-20 | 2022-02-23 | Universität Basel | Virulence attenuated bacteria based protein delivery |
| KR102110993B1 (ko) * | 2018-12-20 | 2020-05-14 | 한국생명공학연구원 | 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 |
| MX2023004760A (es) * | 2020-10-27 | 2023-07-21 | T3 Pharmaceuticals Ag | Suministro de proteinas basado en bacterias. |
| CN114712496B (zh) * | 2022-04-29 | 2023-10-13 | 中山大学·深圳 | 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用 |
| CN116064877B (zh) * | 2023-02-09 | 2024-09-20 | 宁夏大学 | 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法 |
| CN116855496B (zh) * | 2023-07-05 | 2024-08-16 | 郑州大学 | 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用 |
| WO2025037284A2 (en) * | 2023-08-17 | 2025-02-20 | Baccine Ltd. | Genetically modified bacteria for multi-modal secretion of a neoantigen |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| AU2001294834A1 (en) | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| WO2002077249A2 (en) * | 2001-03-26 | 2002-10-03 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| EP1565185A4 (en) | 2002-11-07 | 2011-01-05 | Technion Res & Dev Foundation | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| FR2862312B1 (fr) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| EP1943344A2 (en) | 2005-10-04 | 2008-07-16 | The Ludwig Institute for Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| EP2268313A2 (en) | 2008-03-17 | 2011-01-05 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| AU2012267176B2 (en) | 2011-06-08 | 2017-06-15 | Chelation Partners Incorporated | Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism |
| US9127284B2 (en) * | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| US10143743B2 (en) | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| KR102648293B1 (ko) | 2014-05-21 | 2024-03-15 | 우니페르시테트 바젤 | 세균 기반 단백질 전달 |
| IL259050B2 (en) | 2015-11-19 | 2024-03-01 | Univ Basel | Bacteria-based protein delivery |
| EP3957645A1 (en) | 2016-12-20 | 2022-02-23 | Universität Basel | Virulence attenuated bacteria based protein delivery |
-
2016
- 2016-11-17 EP EP16797930.1A patent/EP3377094B1/en active Active
- 2016-11-17 HR HRP20211191TT patent/HRP20211191T1/hr unknown
- 2016-11-17 HU HUE16797930A patent/HUE055132T2/hu unknown
- 2016-11-17 SI SI201631290T patent/SI3377094T1/sl unknown
- 2016-11-17 EP EP21170509.0A patent/EP3903813A1/en active Pending
- 2016-11-17 BR BR112018009753-5A patent/BR112018009753B1/pt active IP Right Grant
- 2016-11-17 CA CA3003563A patent/CA3003563A1/en active Pending
- 2016-11-17 AU AU2016358257A patent/AU2016358257B2/en active Active
- 2016-11-17 JP JP2018526167A patent/JP7060503B2/ja active Active
- 2016-11-17 DK DK16797930.1T patent/DK3377094T3/da active
- 2016-11-17 LT LTEP16797930.1T patent/LT3377094T/lt unknown
- 2016-11-17 EA EA201890868A patent/EA201890868A1/ru unknown
- 2016-11-17 US US15/773,524 patent/US11166987B2/en active Active
- 2016-11-17 SG SG11201803643TA patent/SG11201803643TA/en unknown
- 2016-11-17 SM SM20210423T patent/SMT202100423T1/it unknown
- 2016-11-17 PL PL16797930T patent/PL3377094T3/pl unknown
- 2016-11-17 PT PT167979301T patent/PT3377094T/pt unknown
- 2016-11-17 BR BR122023024697-7A patent/BR122023024697A2/pt not_active Application Discontinuation
- 2016-11-17 ES ES16797930T patent/ES2880431T3/es active Active
- 2016-11-17 RS RS20210926A patent/RS62152B1/sr unknown
- 2016-11-17 CN CN201680079454.XA patent/CN108472348B/zh active Active
- 2016-11-17 KR KR1020187016568A patent/KR102736981B1/ko active Active
- 2016-11-17 WO PCT/EP2016/078084 patent/WO2017085233A1/en not_active Ceased
- 2016-11-17 IL IL259052A patent/IL259052B2/en unknown
-
2018
- 2018-06-12 ZA ZA2018/03902A patent/ZA201803902B/en unknown
-
2021
- 2021-07-22 CY CY20211100666T patent/CY1124564T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer |